Tumour cell thrombospondn-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor

British Journal of Cancer

Volumn 83, Issue 3, 2000, Pages 298-306

  Albo, D ^a   Rothman, V L ^a   Roberts, D D ^b   Tuszynski, G P ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Pericellular proteolysis; Plasmin; Urokinase plasminogen activator

Indexed keywords

COLLAGEN; LAMININ; PLASMIN; PLASMINOGEN; THROMBOSPONDIN 1; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; BREAST TUMOR; CANCER INVASION; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; METABOLISM; PATHOLOGY; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; PLASMIN; PLASMINOGEN; RECEPTORS, CELL SURFACE; THROMBOSPONDIN 1; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033623990     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1268     Document Type: Article

References (65)

1. Albini A, Iwamoto Y, Kleinman H, Martin G, Aaronson S and Kozlowski J (1987) A rapid in vitro assays for quantitating the invasive potential of tumour cells. Cancer Res 47: 3239-3245
2. Albo D, Arnoletti JP, Castiglioni A, Granick MS, Solomon MP, Rothman VL and Tuszynski GP (1994) Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type I (PAI-I) production and stimulate tumour cell attachment in vitro. Biochem Biophys Res Commun 203. 857-865
3. Albo D, Berger DH, Wang TN, Hu X, Rothman V and Tuszynski, GP (1997) Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumour cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 122: 493-499
4. Albo D, Berger DH and Tuszynski GP (1998) The effect of thrombospondin-1 and TGF-beta I on pancreatic cancer cell invasion. J Surg Res 76: 86-90
5. Arnoletti JP, Albo D, Jhala N, Granick MS, Solomon MP, Atkinson B, Rothman VL and Tuszynski GP (1994) Computer-assisted imaged analysis of tumour sections for a new thrombospondin receptor. Am J Surg 168: 433-436
6. Arnoletti J, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, and Tuszynski GP (1995) Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells, Cancer 76: 998-1005
7. Barnathan R, Kuo A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, Ronne E, Weiner E, Hemkin J and Cines DB (1990) Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood 76: 1795-1806
8. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, and Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor 1 in breast cancer. Int J Cancer 60: 597-603
9. Blasi F, Behrendt N, Cubellis MV, Ellis V, Lund LR and Masucci MT (1990) The urokinase receptor and regulation of cell surface plasminogen activation. Cell Diff Development 32: 247-254
10. Blasi F (1993a) Molecular mechanisms of protease-mediated tumour invasiveness. J Surg Oncol 3 (suppl): 21-23
11. Blasi F (1993b) Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 15: 105-111
12. Busso N, Masur SK, Lazega D, Waxman S and Ossowski L (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126: 259-70
13. Clezardin P, Serre C-M, Trzeciak M-C, Drouin J and Delmas PD (1991) Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction. Cancer Res 51: 2621-2627
14. Clezardin P, Frappart L, Clerget M, Pechoux C and Delmas PD (1993) Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 53: 1421-1430
15. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E and Nenci GG (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 77: 1079-1088
16. Ellis V, Behrendt N and Dano K (1991) Plasminogen activation by receptor bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266: 12752-12758
17. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Kramer MD and Janicke F (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
18. Graeff H, Harbeck N, Pache L, Wilhelm O, Janicke F and Schmitt M (1992) Prognostic impact and clinical relevance of tumour associated proteases in breast cancer. Fibrinolysis 6: 45-53
19. Grondahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brunner N (1997) Prognostic significance of PAI-I and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163
20. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG and Cote RJ (1997) Thrombospondin-1 expression in bladder eancer: association with p53 alterations, tumour angiogenesis, and tumour progression. J Natl Cancer Inst 89: 219-227
21. Hajjar KA (1995) Cellular receptors in the regulation of plasmin generation. Thromb Haemost 74: 294-301
22. Hebert C and Baker JB (1988) Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol 106: 1241-1247
23. Hosokawa T, Muraishi A, Rothman V, Papale M and Tuszynski GP (1993) The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. Oncology Res 5: 183-189
24. Kariko K, Kuo A, Boyd D, Okada SS, Cines DB and Barnathan ES (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53: 3109-3117
25. Keski-Oja J, Koli K, Lohi L and Laiho M (1991) Growth factors in the regulation of the plasminogen plasmin-system in tumour cells. Semin Thromb Hemost 17: 231-239
26. Kook YH, Adamski J, Zelent A and Ossowski L (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983-3991
27. Krishnamurti C and Alving B (1992) Plasminogen activator inhibitor type 1: biochimestry and evidence for modulation of fibrinolysis in vivo. Semin Tromb Hemost 18: 67-80
28. Laiho M and Keski-Oja J (1989) Growth factors in the regulation of pericellular proteolysis. Cancer Res 49: 2533-2553
29. Mignatti P and Rifkin DB (1993) Biology and biochemistry of proteinascs in tumour cell invasion. Physiol Rev 73: 161-195
30. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D and Rao JS (1993) Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143-4147
31. Mohanam S, Sawaya RE, Yamamoto M, Bruner JM, Nicholson GL and Rao JS (1994) Proteolysis and invasiveness of brain tumours: role of urokinase-type plasminogen activator receptor. J Neurooncol 22: 153-160
32. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR and Tuszynski GP (1994) Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 73: 2853-2858
33. Ossowski L, Clunie G, Masucci MT and Blasi F (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumour cell invasion. J Cell Biol 115: 1107-1112
34. Ossowski L (1992) Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 52: 6754-6760
35. Ploug M, Kjalke M, Ronne E, Weidle U, Hoyer-Hansen G and Dano K (1993) Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 268: 17539-17546
36. Plow E, Freaney DE, Plescia J and Miles LA (1986) The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 103: 2411-2420
37. Pollanen J, Saksella O, Salonen EM, Andreasen P, Nielsen L, Dano K and Vaheri A (1987) Distinct localizations ot urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085-1096
38. Pollanen J, Hedman K, Nielsen LS, Dano K and Vaheri A (1988) Ultrastructural localization of plasma-membrane associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 106: 87-95
39. Roldan A, Cubellis MV, Masucci N, Behrendt LR, Lund K, Dano E Appela E and Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474
40. Roth JJ, Reiver DM, Granick MS, Rothman VL, Nicosia RF and Tuszynski GP (1997) Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumours. Histol Histopathol 12: 1013-1018
41. Schultz-Cherry S and Murphy-Ullrich JE (1993) Thromhospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 122: 923-932
42. Schultz-Cherry S, Lawler J and Murphy-Ullrich JE (1994a) The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β. J Biol Chem 269: 26783-26788
43. Schultz-Cherry S, Ribeiro S, Gentry L and Murphy-Ullrich, JE (1994b) Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 269: 26775-26782
44. Seiffert D, Ciambrone G, Wagner NV, Binder BK and Loskutoff DJ (1994) The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type I plasminogen activator inhibitor. J Biol Chem 269: 2659-2666
45. Testa JE and Quigley JP (1990) The role of urokinase-type plasminogen activator in aggressive tumour cell behavior. Cancer Metastasis Rev 9: 353-367
46. Tuszynski GP (1993) The role of thrombospondin in malignancy and tumour cell metastasis. In: Thrombospondin, Lahav J (ed) pp. 209-225. CRC Press: Boca Raton
47. Tuszynski GP and Murphy A (1990) Spectrophotometric quantitation of anchorage-dependent cell numbers using the bicinchoninic acid protein assay reagent. Anal Biochem 184: 189-191
48. Tuszynski GP and Nicosia RF (1994) Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest 70: 228-233
49. Tuszynski GP and Nicosia RF (1996) The role of thrombospondin-1 in tumour progression and angiogenesis. BioEssays 18: 71-76
50. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA and Gasic GJ (1987a) Thrombospondin, a potentiator of tumour cell metastasis. Cancer Res 47: 4130-4133
51. Tuszynski GP, Rothman V, Murphy A, Siegler K, Smith L, Smith S, Karczewski J and Knudsen KA (1987b) Thrombospondin promotes cell-substratum adhesion. Science 236: 1570-1573
52. Tuszynski GP, Switalska HI and Knudsen K (1987c) Methods of studying platelet-secreted proteins and the platelet cytoskeleton. Mod Meth Pharm 4: 267-286
53. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J, Besa EC, Treat J and Switalska HI (1992) Thrombospondin levels in patients with malignancy. Thromb Haemost 67: 607-611
54. Tuszynski GP, Wang TN and Berger D (1997) Adhesive proteins and the hematogenous spread of cancer. Acta Haematologica 97: 29-39
55. Vassalli J, Baccino D and Belin D (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92.
56. Vassalli J, Sappino AP and Belin D (1991 ) The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072
57. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL and Tuszynski GP (1995) The effect of thrombospondin (TSP) on oral squamous carcinoma cell invasion of collagen. Am J Surg 170: 502-505
58. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH and Tuszynski GP (1996a) Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63: 39-43
59. Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH and Tuszynski GP (1996b) Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 120: 449-454
60. Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH and Tuszynski GP (1996c) Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63: 39-43
61. Weinstat-Saslow, DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD and Steeg PS (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumour growth, metastatic potential, and angiogenesis. Cancer Res 54: 6504-6511
62. Wong SY, Purdie AT and Han P (1992) Thrombospondin and other possible related matrix proteins in malignant and benign breast disease: An immunohistochemical study. Am J Pathol 140: 1473-1482
63. Yabkowitz R, Mansfield PJ, Dixit VM and Suchard SJ (1993) Motility of human carcinoma cells in response to thrombospondin: Relationship to metastatic potential and thrombospondin structural domains. Cancer Res 53: 378-387
64. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T and Shirakusa T (1998) Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 82: 632-638
65. Yu W, Kim J and Ossowski L (1997) Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 137: 767-777